Relmada Therapeutics (STU:4E2) Short-Term Capital Lease Obligation : €0.00 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Short-Term Capital Lease Obligation?

Relmada Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil.

Relmada Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Relmada Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Short-Term Capital Lease Obligation Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

Relmada Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Relmada Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Relmada Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines